Ozempic—and 14 other popular prescription drugs—will cost less for Medicare after the U.S. government negotiated lower prices

The Trump administration announced negotiated prices for 15 drugs under Medicare, which, if implemented last year, could have saved Medicare $12 billion, reducing spending on these medications by 44 percent. The list includes commonly used inhalers like Breo Ellipta, as well as treatments for cancer, diabetes, and depression.

The Centers for Medicare and Medicaid Services announced a significant reduction in prices for 15 prescription drugs, including popular medications Ozempic and Wegovy, aimed at improving access for Medicare beneficiaries. This move is part of ongoing efforts to manage healthcare costs and enhance affordability for patients relying on these treatments.

A new study has revealed that individuals with untreated obstructive sleep apnea are nearly twice as likely to develop Parkinson’s disease, highlighting a significant health concern associated with this sleep disorder.

Novo Nordisk's trials of semaglutide, marketed as Ozempic and Wegovy, have failed to demonstrate any cognitive benefits for individuals with mild cognitive impairment or dementia, marking a significant setback for the company's ambitions to expand the drug's applications beyond obesity and diabetes treatment.

Novo Nordisk announced that a pill containing the key ingredient from its diabetes and weight-loss drugs, Ozempic and Wegovy, did not demonstrate efficacy in slowing the progression of Alzheimer’s disease during two late-stage clinical trials. This outcome raises concerns about the potential of these medications in treating neurodegenerative conditions.